+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the combination of BP1001 plus venetoclax plus decitabine in adults with acute myeloid leukemia AML who cannot or choose not to receive intensive chemotherapy. The study aims to determine if this combination offers better results, such as complete remission, compared to venetoclax plus decitabine alone or to intensive chemotherapy in patients with untreated or relapsedrefractory AML. This Phase IIa trial focuses on patients who are fragile or ineligible for aggressive treatment, addressing a need for targeted therapies that may improve outcomes while being tolerable. Participants will receive one of three treatment combinations depending on their AML status untreated patients receive BP1001 with venetoclax and decitabine relapsed or refractory patients receive BP1001 with venetoclax and decitabine and a third group of relapsed or refractory patients who are resistant or intolerant to venetoclax receive BP1001 plus decitabine. The study uses an open-label design and will enroll about 19 participants per cohort initially, with potential expansion based on interim data review. The treatment involves multiple drug administrations to assess safety, pharmacokinetics, pharmacodynamics, and efficacy. During the study, participants will undergo regular assessments including bone marrow biopsies or aspirates to measure treatment response over 180 days. Safety will be monitored through evaluations up to 30 days post-treatment, along with pharmacokinetic studies of BP1001. Researchers will also assess minimal residual disease status and overall survival. Participants must meet specific health criteria and will provide informed consent before enrollment. The study is sponsored by Bio-Path Holdings, Inc. and is expected to continue until December 2028.

Age: 18Years +All GendersPhase 2
9 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
P

Actively Recruiting

Researchers are conducting a pilot Type 1 Hybrid Effectiveness-Implementation Trial to evaluate a tailored lung screening intervention in patients at risk for lung cancer. The study focuses on using an Electronic Health Record-embedded Social Determinants of Health SDoH screening tool in the Emergency Department to identify eligible patients and increase lung cancer screening uptake. The trial aims to assess the reach and preliminary effectiveness of this intervention in comparison with enhanced usual care by examining factors such as health literacy, mistrust, stigma, fatalism, knowledge, and lung screening health beliefs. The study compares two groups one receiving LungTalk, a tailored, interactive educational program delivered via iPad that adapts content based on smoking status and perceived barriers and another receiving a non-tailored lung screening pamphlet emailed to patients along with patient navigation support. LungTalk includes audio, video, and animation to engage participants, while the pamphlet provides standard educational information about lung cancer risk and screening. Participants are identified through SDoH screening and receive tailored or standard educational materials accordingly. Participants aged 50 to 80 who currently smoke or quit within 15 years and have a 20 pack-year smoking history are involved. Researchers will measure lung cancer screening uptake and stage of adoption at 1 week, 1 month, and 6 months post-intervention. Additional assessments include health literacy, medical mistrust, stigma, perceived risk, benefits and barriers to screening, self-efficacy, knowledge, and fatalism at 1 week and 1 month. The study uses randomized methods and collects data from electronic health records to monitor outcomes and reach over the trial period.

Age: 50Years - 80YearsAll GendersPhase Not Applicable
10 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
F

Actively Recruiting

Researchers are studying whether Tamsulosin can reduce the high rate of postoperative urinary retention POUR in older men undergoing thoracic cancer surgery. POUR is common, especially in older men with enlarged prostates, and can lead to infections, discomfort, longer hospital stays, and other complications. This early phase study aims to determine if taking Tamsulosin before surgery lowers the incidence of POUR and helps patients regain normal urinary function sooner. Participants will take Tamsulosin 0.4 mg daily for seven days before their planned thoracic oncological surgery. They will also record their medication use in a diary. On the day of surgery, they will take Tamsulosin with a sip of water. After surgery, bladder ultrasounds will measure urine volume and retention to assess POUR. Standard bladder care will be provided if spontaneous urination does not occur or if urine residual is high, following a specific management plan. During the study, researchers will monitor spontaneous urination within 6 to 8 hours after surgery, the time and volume of urination within 24 hours, and the amount of urine left in the bladder. They will also track how many participants need medical intervention due to inability to urinate. Monitoring will help assess Tamsulosins potential to prevent urinary retention after surgery. The study is expected to be completed by June 2027.

Age: 55Years +MALEEarly Phase 1
4 locations
P

Actively Recruiting

Researchers are collecting observational data to evaluate the safety and performance of the Serranator4 balloon catheter in treating peripheral artery disease PAD and dysfunctional native or synthetic arteriovenous dialysis fistulae. This registry study observes patients treated under routine medical care to gather real-world evidence for clinical evaluation. Participants will undergo serration balloon angioplasty targeting arteries such as the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and pedal arteries, or dysfunctional dialysis fistulae. The study includes subjects with claudication or ischemic rest pain who have new or recurrent lesions in these areas. During the study, data on peri-procedural performance and safety endpoints will be collected while participants receive standard care. The researchers will monitor outcomes related to the devices use in real-world settings. Participation involves observation and data gathering without altering usual treatment, continuing until the study ends in August 2026.

Age: 18Years +All Genders
19 locations
G

Actively Recruiting

Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.

Age: 1Year +All Genders
11 locations
E

Actively Recruiting

Researchers are evaluating the effect of atezolizumab, alone or combined with recombinant human hyaluronidase, compared to standard observation in preventing the return of stage I non-small cell lung cancer NSCLC after complete surgical removal. This phase III trial focuses on patients who have undergone surgical resection and aims to see if these immunotherapies may better prevent cancer recurrence than usual monitoring. Atezolizumab is a monoclonal antibody that may help the immune system attack cancer cells, and the combination with hyaluronidase may improve drug absorption. Participants are randomly assigned to one of two groups. One group undergoes observation with regular CT scans and optional blood sample collection for one year. The other group receives atezolizumab intravenously or atezolizumab with hyaluronidase subcutaneously every three weeks for up to one year 17 cycles, alongside similar monitoring. After treatment, patients are followed up at 30 days atezolizumab group only, then every 6 months for 3 years, and annually for an additional 7 years, totaling 10 years of follow-up. During the study, participants will have regular CT scans and may provide blood samples to help assess their health and disease status. Researchers will monitor disease-free survival, overall survival, recurrence rates, and adverse events over up to 10 years. Safety and treatment effects will be closely observed throughout treatment and follow-up to understand long-term outcomes and potential benefits of the therapies compared to observation alone.

Age: 18Years +All GendersPhase 3
133 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations